180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that, following publication of promising data from a phase 2b Dupuytren’s trial in the June 2022 issues of The Lancet Rheumatology, 180 Life Sciences has initiated preliminary consultations with regulatory agencies in both the U.K. and U.S., with assistance from its regulatory advisor, Kinexum. At a May 18, 2022, scientific advice meeting with the Medicines and Healthcare products Regulatory Agency (“UK MHRA”), the company presented results of the phase 2b trial and received guidance on the path forward for further development. 180 Life Sciences awaits formal feedback from UK MHRA. In addition, the U.S. Food and Drug Administration (“US FDA”) has agreed to provide a written response to the company’s briefing materials, including the results of the phase 2B trial, with the FDA guidance expected to shape the company’s clinical development strategy in the U.S. “We believe our recent results present the potential for an earlier treatment for patients with Dupuytren’s disease, which is easy to diagnose at an early stage,” said James Woody, M.D., chief executive officer of 180 Life Sciences. “We look forward to feedback from the regulatory agencies, which we believe may help us bring this potential treatment to patients to prevent the disease from advancing to the stage that surgery is needed to maintain hand function.”
To view the full press release, visit https://ibn.fm/1Kq7D
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.